Uploaded November 2026 | Updated November 2026, 7 hours ago
Despite the introduction of whole-genome sequencing (WGS) for the diagnosis of rare diseases, a genetic cause is not identified in the majority of patients. My talk will describe on a proof-of-principle study to explore the potential of scalable blood proteomics to improve the diagnostic yield in patients with a rare disease part of the 100,000 Genomes project (100kGP), including 358 which remained without a genetic diagnosis after WGS. Proteomic profiling targeting 1463 unique proteins was performed using the Olink Explore 1536 assay in stored serum samples.
For 32 undiagnosed patients, we identified likely diagnostic variants by detecting significant lower serum protein levels together with independent variant prioritisation for the corresponding protein encoding gene through either Exomiser, Genomic England’s diagnostic pipeline, or targeted re-analysis. This represents a considerable number of new diagnoses given that the Olink Explore 1536 platform covered only a median of 10% (range: 1.2 - 40%) of the protein products of disease-causing genes across all gene panels tested in all patients (i.e. from PanelApp) . A total of 62% of new diagnoses were linked to genes not previously reported for the respective rare disease. For example, two unrelated patients with rhabdomyolysis and the same heterozygous missense variant in SETMAR (minor allele frequency (MAF) in gnomAD = 0.001% and not present in any other of the 63,356 100kGP individuals) showed lower serum levels of SETMAR (z-scores LT -3). We further identified a heterozygous missense variant (MAF in gnomAD = 0.006%) in TIE1 in a patient with lower levels of TIE1 (z-score = -5.12) affected by an ultra-rare monogenic cardiac disorder. The variant was not present in any other 100kGP individual, except for the proband’s undiagnosed father, affected by the same condition. Missense (52.8%) and splice region (~28%) variants accounted for the majority of new diagnostic variants.
Our proof-of-principle study demonstrates the potential of scalable blood proteomics to support rare disease diagnoses and identify new disease-causing genes in patients undiagnosed after WGS. Successful implementation will likely differ by clinical specialty and depend on factors including tissue specificity of protein expression, detectability in blood, proteomic platform coverage, and assay sensitivity.
Speaker: Julia Carrasco Zanini Sanchez, PhD, Queen Mary University of London
Despite the introduction of whole-genome sequencing (WGS) for the diagnosis of rare diseases, a genetic cause is not identified in the majority of patients. My talk will describe on a proof-of-principle study to explore the potential of scalable blood proteomics to improve the diagnostic yield in patients with a rare disease part of the 100,000 Genomes project (100kGP), including 358 which remained without a genetic diagnosis after WGS. Proteomic profiling targeting 1463 unique proteins was performed using the Olink Explore 1536 assay in stored serum samples.
For 32 undiagnosed patients, we identified likely diagnostic variants by detecting significant lower serum protein levels together with independent variant prioritisation for the corresponding protein encoding gene through either Exomiser, Genomic England’s diagnostic pipeline, or targeted re-analysis. This represents a considerable number of new diagnoses given that the Olink Explore 1536 platform covered only a median of 10% (range: 1.2 - 40%) of the protein products of disease-causing genes across all gene panels tested in all patients (i.e. from PanelApp) . A total of 62% of new diagnoses were linked to genes not previously reported for the respective rare disease. For example, two unrelated patients with rhabdomyolysis and the same heterozygous missense variant in SETMAR (minor allele frequency (MAF) in gnomAD = 0.001% and not present in any other of the 63,356 100kGP individuals) showed lower serum levels of SETMAR (z-scores LT -3). We further identified a heterozygous missense variant (MAF in gnomAD = 0.006%) in TIE1 in a patient with lower levels of TIE1 (z-score = -5.12) affected by an ultra-rare monogenic cardiac disorder. The variant was not present in any other 100kGP individual, except for the proband’s undiagnosed father, affected by the same condition. Missense (52.8%) and splice region (~28%) variants accounted for the majority of new diagnostic variants.
Our proof-of-principle study demonstrates the potential of scalable blood proteomics to support rare disease diagnoses and identify new disease-causing genes in patients undiagnosed after WGS. Successful implementation will likely differ by clinical specialty and depend on factors including tissue specificity of protein expression, detectability in blood, proteomic platform coverage, and assay sensitivity.
Speaker: Julia Carrasco Zanini Sanchez, PhD, Queen Mary University of London










